OCT devices hold promise

Article

Improved imagery could help physicians learn more about diseases and treatment response

New optical coherence tomography (OCT) devices are in development with the goal of expanding the utility of OCT in the clinic by providing better resolution, faster speed, and software to help clinicians better understand the nuances of diseases and how they respond to therapy. Dr Jay S. Duker looked at the past, present and future of the technology during the Retina Subspeciality Day at the annual meeting of the American Academy of Ophthalmology.

The first OCTs that became commercially available in 1996 were time-domain (TD) instruments. Those reached their pinnacle in 2002 when the Stratus OCT was introduced by Zeiss. That instrument, which had 10 μm axial resolution and obtained 400 axial scans per second, remained the state-of-the-art technology until recently.

Over the past decade, many new OCT instruments have become available that are all based on Fourier-domain detection. Spectral-domain (SD) OCT became commercially available in 2006 and swept-source OCT is being used in research but is not yet commercially available. SD-OCT is faster than TD-OCT and can obtain from 20000 to 52000 scans per second. It also has a broader band width that increases the axial resolution from 4 to 7 μm.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.